Comparative review outlines regulatory frameworks for DMF submissions in API manufacturing, suggesting pathways for improvement.
The globalization of pharmaceutical manufacturing has significantly increased the need for transparent, efficient, and harmonized regulatory pathways for Drug Master File (DMF) submissions. Active Pharmaceutical Ingredient (API) manufacturers play a critical role in ensuring the quality, safety, and consistency of drug substances supplied to formulation companies worldwide. To safeguard public health, regulatory agencies such as the United States Food and Drug Administration (USFDA) and the Central Drugs Standard Control Organization (CDSCO), India, have established structured DMF submission frameworks that allow manufacturers to confidentially submit detailed information about API development, manufacturing, quality controls, and stability data.
No takes yet. Share an insight, caveat, or question.
Jejerao* et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: